Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
24 participants
INTERVENTIONAL
2014-10-31
2015-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of a Multi-Ingredient Pre-Workout Supplement on Energy Expenditure During Running
NCT04352998
Effects of a Pre-Workout on Performance, Perceptual Responses, Energy Feelings and Muscular Properties, After a Training Microcycle in Adults.
NCT04147741
Influence of Caffeinated and Non-caffeinated Pre-workout Supplements on Resistance Exercise Performance
NCT04712578
The Acute Effects of Liquid IV's Pre-Workout Supplement on Muscle Endurance & Strength, Energy, and Cognition
NCT07225608
Assessment of a Pre-Workout Supplement
NCT03022604
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Beverage A
Single dose, Pre-Workout Master Performance Blend Dose 1
Master Performance Blend Dose 1
Caffeine content: 200 mg
Beverage B
Single dose, Pre-Workout Master Performance Blend Dose 2
Master Performance Blend Dose 2
Caffeine content: 400 mg
Beverage C
Single dose, Pre-Workout Performance Energy Blend
Performance Energy Blend
Caffeine content: 175 mg
Beverage D
Single dose, Pre-Workout Energy Blend
Energy Blend
Caffeine content: 200 mg
Beverage E
Single dose, Pre-Workout Placebo
Placebo
Caffeine content: 0 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Master Performance Blend Dose 1
Caffeine content: 200 mg
Master Performance Blend Dose 2
Caffeine content: 400 mg
Performance Energy Blend
Caffeine content: 175 mg
Energy Blend
Caffeine content: 200 mg
Placebo
Caffeine content: 0 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject has a waist circumference ≤ 97 cm.
3. Subject is a non-smoker.
4. Subject is in good health and appropriate for exercise as determined by physical examination, medical history and ECG.
5. Subject is weight training for the 6 months prior to starting the trial.
6. Subject agrees to not use any new vitamins and/or minerals until after study completion and to not take any vitamins and/or minerals 24 hours prior to the test visits.
7. Subject agrees to not use any dietary or herbal supplements until after study completion. A 7-day washout is allowed for study inclusion.
8. Subject is willing and able to comply with the protocol including:
* Attending 5 visits each of which is approximately 4 hours long;
* Refraining from caffeine, over-the-counter medications and alcohol for the 24 hours prior to the test visits;
* Refraining from weight training for the 48 hours prior and refraining from any exercise other than weight training for 24 hours prior to the test visits;
* Refraining from taking any dietary or herbal supplements throughout the study.
9. Subject is able to understand and sign the informed consent to participate in the study.
Exclusion Criteria
* active heart disease
* uncontrolled high blood pressure (≥ 140/90 mmHg)
* renal or hepatic impairment/disease
* Type I or II diabetes
* bipolar disorder
* pulmonary disease (including current asthma)
* Parkinson's disease
* Seizure disorder
* unstable thyroid disease
* immune disorder (such as HIV/AIDS)
* active psychiatric disorders (including anxiety disorders)
* bleeding disorders
* gastrointestinal ulcer disease
* any medical condition deemed exclusionary by the Principal Investigator (PI)
2. Subject has any orthopedic problem(s) or history of musculoskeletal injury(ies) which make(s) resistance weight training contraindicated.
3. Subject has a history of cancer (except localized skin cancer without metastases) within 5 years prior to screening.
4. No prescription or chronic medication use allowed without PI discretion.
5. Subject is currently taking and unwilling to refrain from taking any over-the-counter stimulant medications/supplements (see section 2.6.2); seven-day washout required for study inclusion.
6. Subject is currently taking and unwilling to refrain from taking any over-the-counter allergy or asthma medication containing pseudoephedrine or ephedrine (see section 2.6.2); seven-day washout required for study inclusion.
7. Subject has an allergy to milk and phenylalanine, or any of the ingredients in the test product (see section 3.2.1).
8. Subject reports sensitivity to caffeine and/or beta-alanine.
9. Subject reports being a regular caffeine consumer defined as consuming \> 600 mg of caffeine per day.
10. Subject exhibits evidence of hepatic or renal dysfunction as evidenced by ALT, AST, AP being ≥ two times the upper limit of normal or serum creatinine value ≥ 2.0 mg/dl or other clinically significant abnormal clinical laboratory value per PI discretion.
11. Subject has a clinically relevant abnormality as defined by the PI or interpreting physician with respect to the ECG.
12. Subject has a QTcB interval \> 450 msec.
13. Subject has a history of drug or alcohol abuse in the past 12 months.
14. Subject has any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the subject or the quality of the study data.
15. Subject has taken an investigational product within 30 days of the first exercise test visit (visit 2).
18 Years
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glanbia Performance Nutrition
UNKNOWN
Miami Research Associates
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Miami Research Associates
Miami, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GPN-2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.